|
|
|
|
Onyx pursues late-stage cancer drug trial
A late-stage trial of Onyx Pharmaceuticals Inc.s next-generation cancer drug carfilzomib will move forward with the FDAs blessing.The Emeryville company (NASDAQ: ONXX) said it agreed to a special protocol assessment, or SPA, that includes Food and Drug...
|
|
|
Onyx pursues late-stage cancer drug trial
A late-stage trial of s next-generation cancer drug carfilzomib will move forward with the FDAs blessing.The Emeryville company (NASDAQ: ONXX) said it agreed to a special protocol assessment, or SPA, that includes Food and Drug Administration input on the...
|
|
|
Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Car
EMERYVILLE, Calif.'The SPA enables us to initiate this carfilzomib Phase 3 combination trial in the first half of this year with increased clarity on the full approval pathway,' said Michael Kauffman Dr. Kauffman continued, 'This planned Phase 3 study...
|
|
|
New market research report on special purpose needles
Anthem Blue Cross and California Regional Hospital Associations join in patient safety collaborativeAnthem Blue Cross, along with California's three regional Hospital Associations, and the National He...Data evaluating combination therapy with REVLIMID...
|
|
|
Financial Report: Celgene 4Q09
Celgene 4Q09 4Q Revenues: $761 million (+21%) 4Q Earnings: $254 million (loss of $154 million in 4Q08) FY Revenues: $2.7 billion (+19%) FY Earnings: $776 million (loss of $1.5 billion in FY08) Comments: Revlimid sales were up 29% to $1.Financial Report...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q - VIDAZA Fourth Quarter Global Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q - VIDAZA Fourth Quarter Global Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
Companies mentioned in this article: Celgene Corporation SUMMIT, N.J.-- (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales...
|
|
|
Celgene reports total revenue of $758M for fourth-quarter of 2009
Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased 35 Percent to $497 Million Global VIDAZA Net Product Sales Increased 68 Percent to $117 Million Global THALOMID Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
SUMMIT, N.J.- (BUSINESS WIRE) - Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: 2009 Full Year Financial Results Year-Over-Year: 2010 Financial Outlook Year-Over-Year Recent Developments and Highlights Inflammation and Immunology Selected Corporate...
|
|
|
Celgene Sees 4Q Profit On Sales Boost, Lower Costs
SUMMIT, N.J.--Biotech drugmaker Celgene Corp.on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million,...
|
|
|
Celgene reports 4th-quarter profit on cancer drug sales boost, lower research costs
SUMMIT, N.J.Biotech drugmaker Celgene Corp. on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million,...
|
|
|
Telik Initiates Ezatiostat Hydrochloride Phase 1 Study
Telik has initiated Phase 1 clinical study to evaluate ezatiostat hydrochloride (Telintra, TLK199) tablets in combination with lenalidomide (Revlimid) in patients with myelodysplastic syndrome (MDS).The Phase 1 trial is an open label, multicenter, dose...
|
|
|
BiomedReports: News and FDA Updates for Spectrum (Nasdaq:SPPI), Telik (Nasdaq:TELK)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
PALO ALTO, Calif., Jan.25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 1 clinical study to evaluate ezatiostat hydrochloride (TELINTRA, TLK199) tablets in combination with lenalidomide (Revlimid) in...
|
|
|
Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets
Companies mentioned in this article: Telik, Inc.PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 1 clinical study to evaluate ezatiostat hydrochloride (TELINTRA, TLK199) tablets in...
|
|
|
Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revli
PALO ALTO, Calif., Jan.25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 1 clinical study to evaluate ezatiostat hydrochloride (TELINTRA, TLK199) tablets in combination with lenalidomide (Revlimid) in...
|
|
|
DHMC patient surveillance system decreases adverse events in postoperative care
Medizone International files second patent application for AsepticSureFollowing the recently announced success achieved during the third round of trials at its research f...Study results comparing REVLIMID regimen to stem cell transplant in multiple...
|
|
|
Health Canada approves Novartis' Afinitor to treat patients with mRCC
Novartis Pharmaceuticals Canada Inc.(Novartis) announced today that Afinitor(R) (everolimus), a onc...Omni Hotels & Resorts partners with GHA to host "Lasso for Life" eventTop marketing representatives of Omni Hotels & Resorts and the other Global...
|
|
|
Celgene Corporation (NASDAQ:CELG) Acquires Cloucester Pharmaceuticals
Rochester, New York 1/18/2010 09:30 PM GMT (TransWorldNews) Celgene Corporation (NASDAQ:CELG) has announced that it has acquired Gloucester Pharmaceuticals.The transaction closed for $340 million, after the early termination of the applicable waiting period...
|
|
|
Celgene Corporation Reviews 2009 Achievements and Announces 2010 Financial Outlook
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID(R) Fourth Quarter Global Net Product Sales Increased Nearly 35% Y/Y - VIDAZA(R) Fourth Quarter Global Net Product...
|
|
|
Celgene Expands In Cancer Drugs
Recently, Celgene Corporation (CELG) completed the acquisition of the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments.The deal is aimed at bolstering Celgenes portfolio of cancer drugs...
|
|
|
Celgene completes acquisition of Gloucester Pharma
Celgene Corporation has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger agreement Celgene...
|
